Trial Profile
A trial to identify patient characteristics that predict effective eltrombopag dosage for the treatment of Hepatitis C virus (HCV)-related thrombocytopenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2016
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- 29 Jun 2016 New trial record